The XS® Pichia & E.coli Expression Systems
XS Technologies® are the microbial expression systems for today’s therapeutics. With good yields, they merge simplicity and scalability. The XS Technologies® platform can help accommodate industry trends, eliminate production bottlenecks, align downstream processing and drive breakthroughs into the clinic.
XS® Pichia Expression System
Lonza’s XS® Pichia is best in class for complex, non-glycosylated protein production. Its features include:
- Bacteria-like short fermentation time
- Simple and fast strain development
- Methanol-free fermentation
- No viral clearance required
- Highly pure product
- Protein secretion
- No endotoxin
XS® E.coli
E.coli is one of the most trusted and established organisms for the expression of simple to moderately complex biologics. Its features include:
- Reduced antibiotic requirements
- Simpler downstream processes
- Robust upstream processes
- Tunable expression
- Easy scalability
- High titers
One toolbox of expression system components enables you to screen and make impactful choices
Pichia bridges the gap between bacterial and mammalian expression systems, bringing the best of both worlds
Pichia pastoris is a versatile expression system that combines the advantages of other commonly used platforms. Like E.coli, Pichia strains are simple and fast to develop, and achieves high yields in reasonable fermentation times with no need for viral clearance. Like mammalian cells, Pichia is free of endotoxin and secretes a pure, high-quality product, eliminating the need to lyse cells.
Lonza’s glucose-inducible and methanol-free XS® Pichia system is designed to reduce host cell impurities, while folding and assembling more complex proteins to secrete them into the supernatant. Features of this system facilitates ready scalability and simpler downstream processing.
Tools for Developing Successful Biologics
XS® E.coli enables optimized expression of simple to moderately complex proteins. Its robust processes help improve productivity and overall speed to market for your biologic.
The XS® E.coli Expression System includes multiple hosts, several signal sequences and three novel induction systems.
Key benefits of these induction systems include:
- Reduced requirement for antibiotics
- Robust and scalable upstream processes
- Tunable expression to simplify downstream processing
- High titers
- Baseline expression does not need to repressed
Combine three alternative promoter systems with other elements to optimize the expression of your biologics and increase your success rates.
Complexity solved with high productivity and robust processes with XS Technologies® expression toolbox
One toolbox of expression system components enables you to screen and make impactful choices.
Diversity of biotherapeutics requires a toolbox approach for expression options. XS Technologies® (including the XS® Pichia and E.coli Expression Systems) is an extensive expression toolbox. Under license, you can use this platform in your lab and access Lonza’s support where you need it the most. It is the same highly productive and scalable platform we use for our in-house services - so you can be confident in its ability.
Host-screening and support from our technical team will help you choose which system would work best for your molecule.
Services enabled by this technology
Strain development and cell banking
Benefit from more than 30 years of innovation in microbial biotechnology and get access to our toolbox of strain design options which provide the greatest probability of delivering a commercially viable strain that meets product quality targets and titers suitable for future market demand.
Our locations
Our R&D Center of Excellence
Visp, Switzerland
Founded in 1897, Lonza today is a dedicated strategic manufacturing partner to the healthcare industry, working with customers in the pharma, biotech and nutrition markets. Visp remains our largest site in a global network of more than 30 sites and one of the most significant for research and development, development and manufacturing.
Our Visp site is a complex of industry-leading facilities specializing in the development and manufacture of products for pharmaceutical applications including mammalian and microbial biopharmaceuticals, small molecules, highly potent APIs, peptides and bioconjugates including antibody-drug conjugates (ADCs). It is also home to our pioneering Ibex® Solutions services offering: Ibex® Solutions enables customers to accelerate their path throughout the complete biopharmaceutical lifecycle - from preclinical to commercial stages, from drug substance to drug product, all in one location.
Sign up. Stay up-to-date.